Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-874 (briakinumab) in moderate to severe chronic plaque psoriasis
NCT00292396Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2005
- Primary completion
- Apr 2008
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of briakinumab in plaque psoriasis (6 arms), sponsored by AbbVie Inc. Primary endpoint: Proportion of subjects with clinical response relative to Baseline PASI score at 60 weeks. Started Nov 2005; status: completed.
02
Drugs
briakinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00292396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00292396.